Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–239 of 239 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Buffered Saline Clear all

Conditions: Dry Eye
Interventions: Restylane Defyne; Device
Lead sponsor: John C Meyer, MD; Other
Eligibility: 21 Years to 80 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Cerebrovascular Accident
Interventions: GSK249320 100/mg, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 6
States / cities: Orange, California • Jacksonville, Florida • Peoria, Illinois + 3 more

Conditions: Cholera
Interventions: PXVX0200, Placebo; Biological
Lead sponsor: Bavarian Nordic; Industry
Eligibility: 46 Years to 64 Years
Enrollment: 398 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 16
States / cities: Mobile, Alabama • DeLand, Florida • Miami, Florida + 12 more

Conditions: Streptococcus Pneumoniae
Interventions: PG4 vaccine in Buffer 1 with low dose PA-001, PG4 in Buffer 1 with low dose PA-002, PG4 in Buffer 1 with high dose PA-001, PG4 vaccine in Buffer 1 with high dose PA-002, PG4 vaccine in Buffer 2, 20-valent pneumococcal conjugate vaccine, Saline injection; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 65 Years to 84 Years
Enrollment: 380 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 20
States / cities: Lake Forest, California • Rolling Hills Estates, California • Greenacres City, Florida + 13 more

Conditions: Duchenne Muscular Dystrophy
Interventions: WVE-210201 (suvodirsen), Placebo; Drug
Lead sponsor: Wave Life Sciences USA, Inc.; Industry
Eligibility: 5 Years to 12 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 6
States / cities: New Haven, Connecticut • Atlanta, Georgia • Kansas City, Kansas + 3 more

Conditions: COVID-19
Interventions: Ad26.COV2.S, BNT162b2, mRNA-1273, mRNA-1273.211, mRNA-1273.222, SARS-CoV-2 rS/M1; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 867 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 10
States / cities: Decatur, Georgia • Baltimore, Maryland • New York, New York + 6 more

Conditions: Moderate or Severe Submental Fullness
Interventions: Deoxycholic acid injection, Placebo; Drug
Lead sponsor: Kythera Biopharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 506 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 31
States / cities: Birmingham, Alabama • Beverly Hills, California • Irvine, California + 24 more

Conditions: Osteosarcoma
Interventions: SCRI-E2CAR_EGFRtv1, UB_TT170; Biological · Drug
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 15 Years to 30 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2040
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Healthy Volunteer
Interventions: TRL1068, a human monoclonal antibody; Drug
Lead sponsor: Trellis Bioscience LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Smallpox
Interventions: IMVAMUNE®, Placebo; Biological · Other
Lead sponsor: Bavarian Nordic; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 4,005 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 34
States / cities: Birmingham, Alabama • Anaheim, California • Los Angeles, California + 31 more

Conditions: Chronic Kidney Disease, Stage 4, Chronic Kidney Disease, Stage 5, EBV-Related Lymphoproliferative Disorder, EBV-Related Malignant Neoplasm, Post-Transplant Lymphoproliferative Disorder
Interventions: Biospecimen Collection, Dulbecco''s Phosphate-Buffered Saline, Peptide Vaccine, QS21; Procedure · Drug · Biological
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Plasmodium Falciparum Malaria
Interventions: AMA1-C1/Alhydrogel®, CPG 7909 Oligodeoxynucleotide (VaxImmune®); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Nipah Virus Infection
Interventions: HeV-sG-V, Normal Saline Placebo; Biological
Lead sponsor: Auro Vaccines LLC; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 192 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: HIV Infections
Interventions: VRC-HIVDNA016-00-VP, VRC-HIVADV014-00-VP, VRC-HIVDNA016-00-VP placebo, VRC-HIVADV014-00-VP placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 480 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2010
U.S. locations: 5
States / cities: Birmingham, Alabama • Baltimore, Maryland • Boston, Massachusetts + 2 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Arformoterol Tartrate Inhalation Solution, Placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 45 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 4
States / cities: Medford, Oregon • Portland, Oregon • Philadelphia, Pennsylvania + 1 more

Conditions: Hepatitis E, Immunisation
Interventions: HEV 239, Placebo; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Coronavirus Disease 2019
Interventions: Placebo, Leronlimab (700mg); Drug
Lead sponsor: CytoDyn, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 484 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 18
States / cities: Alexander City, Alabama • Fullerton, California • Los Angeles, California + 14 more

Conditions: Clostridium Difficile
Interventions: VLA84, Placebo; Biological
Lead sponsor: Valneva Austria GmbH; Industry
Eligibility: 50 Years and older
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 7
States / cities: Huntsville, Alabama • Chula Vista, California • La Mesa, California + 4 more

Conditions: Male Pattern Hair Loss
Interventions: HST 001, Phosphate Buffered Saline; Biological · Other
Lead sponsor: Histogen; Industry
Eligibility: 25 Years to 55 Years · Male only
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Encinitas, California

Conditions: Anthrax
Interventions: Anthrax, Alhdryogel or PBS; Biological
Lead sponsor: DynPort Vaccine Company LLC, A GDIT Company; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Meningococcal Vaccines
Interventions: Adjuvanted MCV-5, Non-Adjuvanted MCV-5, Menactra®; Biological
Lead sponsor: PATH; Other
Eligibility: 18 Years to 45 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Immunization; Infection|Transplantation Infection|Influenza, Influenza
Interventions: Fluzone High Dose Inactivated Influenza Vaccine, Fluzone Standard Dose Inactivated Influenza Vaccine; Biological
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Delirium, Sleep
Interventions: Dexmedetomidine, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 50 Years and older
Enrollment: 522 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

A Study to Evaluate the Safety and Effectiveness Assessments of Restylane-Defyne for Punctual Occlusion

Proof of Concept (POC) in Patients With Ischaemic Stroke

A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older Adults

A Study to Learn About How a New Pneumococcal Vaccine Works in Adults

Efficacy and Safety Study of WVE-210201 (Suvodirsen) With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy

Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines

Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area

A Phase I Feasibility And Safety Study of Fluorescein-Specific (FITC-E2) CAR T Cells In Combination With Parenterally Administered Folate-Fluorescein (UB-TT170) For Osteogenic Sarcoma

Study to Evaluate Safety and Activity of Inhaled TRL1068 in Healthy Volunteers

A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects

BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants

AMA1-C1/Alhydrogel + CpG 7909 for Malaria

Safety and Immunogenicity of a Nipah Virus Vaccine

HVTN Protocol 204 - A Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA016-00-VP, Followed by a Multiclade Recombinant Adenoviral Vector HIV-1 Vaccine Boost, VRCHIVADV014-00-VP, in HIV-1 Uninfected Adult Participants

Efficacy Safety Study of Arformoterol QD Dosing Versus BID Dosing in COPD

Safety Study of Hepatitis E Vaccine (HEV239)

Evaluate the Efficacy & Safety of Leronlimab in Patients With Severe or Critical COVID-19

Dose-Confirmation, Immunogenicity and Safety Study of the Clostridium Difficile Vaccine Candidate VLA84 in Healthy Adults Aged 50 Years and Older. Phase II Study

Safety and Efficacy of HST 001 in Male Pattern Hair Loss

A New Anthrax Vaccine Administered by the Intramuscular (IM) Route in Healthy Adults

Study of Meninigococcal Conjugate Vaccine Containing Serogroups A,C,Y,W and X (MCV5) in Healthy Adults

High vs. Standard Dose Influenza Vaccines in Lung Transplant (Repeater)

Investigation of Sleep in the Intensive Care Unit